Silent No More: Protesters Demand Consumer Voice at Tobacco Control Summit
WVA's protest in Dublin
DUBLIN, June 24, 2025 (GLOBE NEWSWIRE) -- On the opening day of the World Conference on Tobacco Control (WCTC) in Dublin, the World Vapers' Alliance staged a silent protest outside the venue, visually highlighting the exclusion of consumers from global tobacco and nicotine policy debates. Demonstrators with their mouths taped symbolised the ongoing marginalisation of those most affected by regulatory decisions.
The protest is part of the 'Voices Unheard—Consumers Matter!' campaign, launched as delegates gathered inside to discuss the future of tobacco control without meaningful input from the consumers who are most impacted by these policies. This exclusion is especially concerning with COP11 in Geneva approaching and the World Health Organization pushing for bans on flavoured nicotine products—a move that would deny adults safer alternatives.
Michael Landl, Director of the World Vapers' Alliance, warned that outdated, ideologically driven policies, often influenced by powerful interests like Michael Bloomberg, threaten to reverse progress in reducing smoking rates. 'Safer nicotine alternatives have the potential to save millions of lives, but only if they are supported by sensible, evidence-based regulation. We cannot afford to let ideology stand in the way of real progress,' Landl said.
The campaign comes at a time when the World Health Organization (WHO) is pushing for sweeping bans on flavoured nicotine products, including e-cigarettes and nicotine pouches. Such measures would remove vital tools from adults seeking to quit smoking and could drive many back to combustible tobacco.
Alberto Gómez Hernández, Policy and Advocacy Manager for the WVA, stressed the importance of listening to consumers. 'Instead of banning flavours and safer alternatives, we need policies that protect both youth and adult smokers who want to quit smoking,' he explained.
The protest underscores the urgent need for genuine consumer inclusion and evidence-based harm reduction as the world prepares for COP11.
For media enquiries and high-resolution images, please contact: Michael Landl info@worldvapersalliance.comWORLD VAPERS' ALLIANCE INC 18117 BISCAYNE BLVD PMB 60190 MIAMI, FL 33160
High-quality pictures of the protest can be found here.
More information about flavour bans: https://worldvapersalliance.com/wp-content/uploads/2025/06/Briefing-WHO-Flavour-Ban.pdf
More about the WVA's demands: https://worldvapersalliance.com/wp-content/uploads/2025/03/Rethinking-Tobacco-control-Report.pdf
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5d4efecb-c0f8-4b11-b8e1-a6ca20c5548a
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval
VADUZ, Liechtenstein, June 24, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the submission of the third and final module of the RefluxStop® pre-market approval (PMA) application with the US Food and Drug Administration (FDA), along with responses to the second module. Implantica submitted the last and final Module 3 of the RefluxStop® PMA application together with the response to Module 2 review findings to FDA yesterday. Module 2, the clinical module, primarily addressed what we believed were minor findings. Module 3 is focused on tests of the product such as bench testing and biocompatibility testing for the RefluxStop® device. In line with the positive feedback in the FDA PMA application process so far, the latest RefluxStop® data submitted as part of the Module 2 response, as well as in the final Module 3, is quite robust and conclusive in Implantica's opinion. We hope the newly submitted data and responses will not only continue to meet the stringent requirements for the PMA approval process but also exceed them. The continued process relies to a large extent now on FDA, which will guide Implantica in the coming steps. FDA's feedback on Module 3 is expected sometime in the autumn. Inventor of RefluxStop®, Founder and CEO of Implantica, Dr. Peter Forsell, says, "I want to extend my gratitude to U.S. FDA for this thorough evaluation process of every facet of a new technology, such as RefluxStop®. Now more than ever, I believe we are on the cusp of a new generation of much needed surgical solutions for GERD with the potential to transform the standard of care for GERD patients in the U.S.." Dr Forsell continues, "This is a significant milestone for Implantica, one we all waited for. Undoubtedly, GERD is a grave and growing issue in the U.S. today, impacting approximately 22-27% of adults in the U.S. population. With over 1300 patients treated across nearly 50 centers in Europe and excellent long-term 5-year data results from the pivotal study, I believe RefluxStop® is poised to help these hugely underserved patients in the U.S. and worldwide in the years to come!" Antunes C, Aleem A, Curtis SA. Gastroesophageal Reflux Disease. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: Kahrilas PJ, Boeckxstaens G, Smout AJ. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):401-14. doi: 10.1016/ PMID: 23998978; PMCID: PMC3761380. Harsányi, L., Kincses, Z., Zehetner, J. et al. Treating acid reflux without compressing the food passageway: 4-year safety and clinical outcomes with the RefluxStop device in a prospective multicenter study. Surg Endosc 38, 6060-6069 (2024). Shih-Chi Ho et al., Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. Digestive Diseases and Sciences, 2002. 47(3): 652-6 For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ The information was sent for publication, through the agency of the contact person set out above, on 24. June 2025, at 08:00 a.m. (CET). About Implantica Implantica is a MedTech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. About RefluxStop™ RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower esophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit. In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower esophageal sphincter in its original, natural position. The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux. Newsroomhttps:// Communityhttps:// Media Contact:Implantica AGJuanita Eberhart, VP Marketing & AdvocacyM: +1 This information was brought to you by Cision The following files are available for download: Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval logo transparent 1 8 ReluxStop Product View original content: Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2 A phase II trial has recently been initiated to investigate the efficacy and safety of LuAG13909 for the potential treatment of CAH3 VALBY, Denmark, June 24, 2025 /PRNewswire/ -- Lundbeck today announces that orphan drug designation has been granted to Lu AG13909 by the US Food and Drug Administration (FDA) on 12 May 2025 and the European Medicines Agency (EMA) on 20 June 2025. Lu AG13909 is a novel, humanised monoclonal antibody, under investigation for the treatment of patients with CAH, a rare genetic disease. CAH is characterised by impaired cortisol production and elevated levels of adrenocorticotropic hormone (ACTH), a hormone produced in the brain and involved in the regulation of multiple functions in the body. Elevated levels of ACTH lead to additional adrenal hormone imbalance, ultimately resulting in multiple developmental disturbances including symptoms related to the central nervous system, and long-term health concerns. "CAH is a life-long condition, requiring constant management. Many existing treatments focus on controlling cortisol levels, however these options are often complicated by side effects. The orphan drug designation for Lu AG13909, our potential first in class anti-ACTH antibody, reflects the program's innovative approach, as well as the high medical need to find new treatments for CAH," said Johan Luthman, EVP and Head of Research and Development at Lundbeck. Lu AG13909 is advancing to mid-stage clinical development, as a new therapeutic approach for conditions marked by elevated ACTH levels, such as CAH. Lundbeck is currently expanding an ongoing Phase I/II clinical open-label trial, evaluating the efficacy and safety of anti-ACTH antibody Lu AG13909 in adults with classic CAH. The trial will open for enrolment in North America and seven countries across Europe, with the first sites opening in late June 2025. The expanded trial will enrol men and women, aged ≥18 to ≤70 years with classic CAH, under stable glucocorticoid dosing. Participants will receive monthly intravenous administrations of Lu AG13909 and will be divided into two cohorts. The first will include participants with hyperandrogenemia, and the second will include participants with normal androgen levels, but treated with supraphysiologic glucocorticoid doses. Participants may enter an optional open-label extension, where they receive monthly Lu AG13909 administration over a period of 12 months. About Lu AG13909Lu AG13909 is a humanised anti-ACTH monoclonal antibody that specifically recognises ACTH with high affinity. It blocks the binding of ACTH to the melanocortin 2 receptor in the adrenal glands and thereby inhibits the neurohormonal signalling of ACTH. This inhibition causes a decreased secretion of glucocorticoids, mineralocorticoids and androgens from the adrenal glands.3,4 ACTH plays a key role in the biosynthesis of adrenal steroids5 and is therefore considered a promising therapeutic target in conditions characterised by elevated ACTH levels.4 In this context, Lu AG13909, a novel molecule, may provide a therapeutic approach for treating conditions associated with chronically elevated ACTH levels. In animal studies, Lu AG13909 has shown significant and durable reductions of corticosterone/cortisol and aldosterone.3 No adverse effects were observed after 6 months of intravenous dosing. About congenital adrenal hyperplasiaClassic CAH is a rare, autosomal recessive disorder1 affecting 1 in 14,000–18,000 live births worldwide.2 Classic CAH is characterised by an enzyme deficiency, most commonly 21-hydroxylase deficiency, affecting the adrenal steroidogenesis leading to cortisol and aldosterone deficiency. People with 21-hydroxylase deficiency are at risk of adrenal crisis, a life-threatening condition contributing to the increased mortality throughout life.6 Balancing physiological glucocorticoid replacement and control of hyperandrogenism remains a challenge with the risk of long-term consequences of glucocorticoid overtreatment.7-9 Contacts Marie Petterson Jens Høyer Head of Media Relations, Corp. Communication Vice President, Head of Investor Relations MEEP@ JSHR@ +45 29 82 21 82 +45 30 83 45 01Palle Holm OlesenVice President, Investor RelationsPALO@ 30 83 24 26 About H. Lundbeck A/SLundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole. Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site and connect with us via LinkedIn. References: Merke DP, Auchus RJ. N Engl J Med 2020;383(13):1248-61 Claahsen-van der Grinten HL, et al. Endocr Rev 2022;43(1):91-159 Lundbeck. Data on file Feldhaus AL, et al. Endocrinology 2017;158(1):1-8 Xing Y, et al. J Endocrinol 2011;209(3):327-35 Lousada LM, et al. Arch Endocrinol Metab 2021;65(4):488-94 Han TS, et al. Nat Rev Endocrinol 2014;10(2):115-24 Pofi R, et al. Clin Endocrinol (Oxf) 2023 Auchus RJ, et al. Front Endocrinol (Lausanne) 2022;13:1005963 CONTACT: H. Lundbeck A/SOttiliavej 9, 2500 Valby, Denmark+45 3630 1311info@ This information was brought to you by Cision The following files are available for download: ACTH ODD Press release_Final View original content: SOURCE H. Lundbeck A/S Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2 A phase II trial has recently been initiated to investigate the efficacy and safety of LuAG13909 for the potential treatment of CAH3 VALBY, Denmark, June 24, 2025 /PRNewswire/ -- Lundbeck today announces that orphan drug designation has been granted to Lu AG13909 by the US Food and Drug Administration (FDA) on 12 May 2025 and the European Medicines Agency (EMA) on 20 June 2025. Lu AG13909 is a novel, humanised monoclonal antibody, under investigation for the treatment of patients with CAH, a rare genetic disease. CAH is characterised by impaired cortisol production and elevated levels of adrenocorticotropic hormone (ACTH), a hormone produced in the brain and involved in the regulation of multiple functions in the body. Elevated levels of ACTH lead to additional adrenal hormone imbalance, ultimately resulting in multiple developmental disturbances including symptoms related to the central nervous system, and long-term health concerns. "CAH is a life-long condition, requiring constant management. Many existing treatments focus on controlling cortisol levels, however these options are often complicated by side effects. The orphan drug designation for Lu AG13909, our potential first in class anti-ACTH antibody, reflects the program's innovative approach, as well as the high medical need to find new treatments for CAH," said Johan Luthman, EVP and Head of Research and Development at Lundbeck. Lu AG13909 is advancing to mid-stage clinical development, as a new therapeutic approach for conditions marked by elevated ACTH levels, such as CAH. Lundbeck is currently expanding an ongoing Phase I/II clinical open-label trial, evaluating the efficacy and safety of anti-ACTH antibody Lu AG13909 in adults with classic CAH. The trial will open for enrolment in North America and seven countries across Europe, with the first sites opening in late June 2025. The expanded trial will enrol men and women, aged ≥18 to ≤70 years with classic CAH, under stable glucocorticoid dosing. Participants will receive monthly intravenous administrations of Lu AG13909 and will be divided into two cohorts. The first will include participants with hyperandrogenemia, and the second will include participants with normal androgen levels, but treated with supraphysiologic glucocorticoid doses. Participants may enter an optional open-label extension, where they receive monthly Lu AG13909 administration over a period of 12 months. About Lu AG13909Lu AG13909 is a humanised anti-ACTH monoclonal antibody that specifically recognises ACTH with high affinity. It blocks the binding of ACTH to the melanocortin 2 receptor in the adrenal glands and thereby inhibits the neurohormonal signalling of ACTH. This inhibition causes a decreased secretion of glucocorticoids, mineralocorticoids and androgens from the adrenal glands.3,4 ACTH plays a key role in the biosynthesis of adrenal steroids5 and is therefore considered a promising therapeutic target in conditions characterised by elevated ACTH levels.4 In this context, Lu AG13909, a novel molecule, may provide a therapeutic approach for treating conditions associated with chronically elevated ACTH levels. In animal studies, Lu AG13909 has shown significant and durable reductions of corticosterone/cortisol and aldosterone.3 No adverse effects were observed after 6 months of intravenous dosing. About congenital adrenal hyperplasiaClassic CAH is a rare, autosomal recessive disorder1 affecting 1 in 14,000–18,000 live births worldwide.2 Classic CAH is characterised by an enzyme deficiency, most commonly 21-hydroxylase deficiency, affecting the adrenal steroidogenesis leading to cortisol and aldosterone deficiency. People with 21-hydroxylase deficiency are at risk of adrenal crisis, a life-threatening condition contributing to the increased mortality throughout life.6 Balancing physiological glucocorticoid replacement and control of hyperandrogenism remains a challenge with the risk of long-term consequences of glucocorticoid overtreatment.7-9 Contacts Marie Petterson Jens Høyer Head of Media Relations, Corp. Communication Vice President, Head of Investor Relations MEEP@ JSHR@ +45 29 82 21 82 +45 30 83 45 01Palle Holm OlesenVice President, Investor RelationsPALO@ 30 83 24 26 About H. Lundbeck A/SLundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole. Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site and connect with us via LinkedIn. References: Merke DP, Auchus RJ. N Engl J Med 2020;383(13):1248-61 Claahsen-van der Grinten HL, et al. Endocr Rev 2022;43(1):91-159 Lundbeck. Data on file Feldhaus AL, et al. Endocrinology 2017;158(1):1-8 Xing Y, et al. J Endocrinol 2011;209(3):327-35 Lousada LM, et al. Arch Endocrinol Metab 2021;65(4):488-94 Han TS, et al. Nat Rev Endocrinol 2014;10(2):115-24 Pofi R, et al. Clin Endocrinol (Oxf) 2023 Auchus RJ, et al. Front Endocrinol (Lausanne) 2022;13:1005963 CONTACT: H. Lundbeck A/SOttiliavej 9, 2500 Valby, Denmark+45 3630 1311info@ This information was brought to you by Cision The following files are available for download: ACTH ODD Press release_Final View original content: SOURCE H. Lundbeck A/S Sign in to access your portfolio
